Atrial fibrillation: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 46: | Line 46: | ||
==[[Atrial fibrillation overview of treatment|Treatment]]== | ==[[Atrial fibrillation overview of treatment|Treatment]]== | ||
===[[Atrial fibrillation anticoagulation]]=== | |||
=== [[Atrial fibrillation anticoagulation]] === | |||
[[Atrial fibrillation anticoagulation|Overview]] | [[Warfarin]] | [[Dabigatran#Converting from or to Warfarin|Converting from or to Warfarin]] | [[Dabigatran#Converting from or to Parenteral Anticoagulants|Converting from or to Parenteral Anticoagulants]] | [[Atrial fibrillation anticoagulation|Overview]] | [[Warfarin]] | [[Dabigatran#Converting from or to Warfarin|Converting from or to Warfarin]] | [[Dabigatran#Converting from or to Parenteral Anticoagulants|Converting from or to Parenteral Anticoagulants]] | ||
==== [[Dabigatran]] ==== | ==== [[Dabigatran]] ==== | ||
[[dabigatran#Dosing|Dosing]] | [[Dabigatran#Surgery and Interventions|Discontinuation for Surgery and Interventions]] | [[Dabigatran#WARNINGS AND PRECAUTIONS| Warnings and Precautions]] | [[Dabigatran#Adverse Reactions|Adverse Reactions]] | [[Dabigatran#Use in Specific Populations|Use in Specific Populations Such as Pregnancy]] | [[Dabigatran#Overdosage|Overdosage]] | [[Clinical Pharmacology of Dabigatran|Clinical Pharmacology]] | [[FDA Review of Data From the RE-LY Trial on September 20th, 2010|FDA Review of the RE-LY Data]] | [[A comparison of the RE-LY and Rocket AF Trials ]] | [[Estimates of Cost Per Year of Life Saved for Dabigatran]] | [[dabigatran#Dosing|Dosing]] | [[Dabigatran#Surgery and Interventions|Discontinuation for Surgery and Interventions]] | [[Dabigatran#WARNINGS AND PRECAUTIONS| Warnings and Precautions]] | [[Dabigatran#Adverse Reactions|Adverse Reactions]] | [[Dabigatran#Use in Specific Populations|Use in Specific Populations Such as Pregnancy]] | [[Dabigatran#Overdosage|Overdosage]] | [[Clinical Pharmacology of Dabigatran|Clinical Pharmacology]] | [[FDA Review of Data From the RE-LY Trial on September 20th, 2010|FDA Review of the RE-LY Data]] | [[A comparison of the RE-LY and Rocket AF Trials ]] | [[Estimates of Cost Per Year of Life Saved for Dabigatran]] | ||
==== Cardioversion ==== | === [[Atrial fibrillation rate control|Rate and Rhythm Control]] === | ||
==== [[Atrial fibrillation rate control|Rate Control]] ==== | |||
[[Atrial fibrillation maintenance of rate control and sinus rhythm|Maintenance of Sinus Rhythm]] | |||
==== '''[[Cardioversion]]''' ==== | |||
[[Atrial fibrillation cardioversion|Overview]] | [[Atrial fibrillation electrical cardioversion|Electrical Cardioversion]] | [[Atrial fibrillation pharmacological cardioversion|Pharmacological Cardioversion]] | [[Atrial fibrillation cardioversion|Overview]] | [[Atrial fibrillation electrical cardioversion|Electrical Cardioversion]] | [[Atrial fibrillation pharmacological cardioversion|Pharmacological Cardioversion]] | ||
==== Ablation ==== | ==== [[Ablation]] ==== | ||
[[Atrial fibrillation catheter ablation|Catheter Ablation]] | [[AV nodal ablation|AV Nodal Ablation]] | [[Atrial fibrillation surgical ablation|Surgical Ablation]] | [[Atrial fibrillation catheter ablation|Catheter Ablation]] | [[AV nodal ablation|AV Nodal Ablation]] | [[Atrial fibrillation surgical ablation|Surgical Ablation]] | ||
==== | ==== [[Atrial fibrillation surgical ablation]] ==== | ||
[[Atrial fibrillation surgical treatment|Maze Open Heart Surgery]] | [[Atrial fibrillation surgical treatment|Maze Open Heart Surgery]] | ||
===[[Atrial fibrillation secondary prevention|Secondary Prevention]]=== | ===[[Atrial fibrillation secondary prevention|Secondary Prevention]]=== | ||
===[[Atrial fibrillation cost-effectiveness of therapy|Cost-effectiveness of Therapy]]=== | ===[[Atrial fibrillation cost-effectiveness of therapy|Cost-effectiveness of Therapy]]=== | ||
Latest revision as of 20:14, 19 November 2024
 |
Resident Survival Guide |
 Sinus rhythm |
 Atrial fibrillation |
|
Atrial Fibrillation Microchapters | |
|
Special Groups | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Cardioversion | |
|
Anticoagulation | |
|
Surgery | |
|
Case Studies | |
|
Atrial fibrillation On the Web | |
For patient information, click here. Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2] Laith Adnan Allaham, M.D.[3] Sem A.O.F. Rikken, M.D.[4]
Synonyms and keywords: AF; afib; lone fibrillator
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Atrial Fibrillation from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Special Groups
Postoperative AF | Acute Myocardial Infarction | Wolff-Parkinson-White Preexcitation Syndromes | Hypertrophic Cardiomyopathy | Hyperthyroidism | Pulmonary Diseases | Pregnancy | Patients Presenting with ACS and/or PCI or Valve Intervention
Diagnosis
History and Symptoms | Physical Examination | Laboratory Findings | Electrocardiogram | EKG Examples | Afib with LBBB EKG Examples | Chest X Ray | Echocardiography | Holter Monitoring and Exercise Stress Testing | Cardiac MRI
Treatment
Atrial fibrillation anticoagulation
Overview | Warfarin | Converting from or to Warfarin | Converting from or to Parenteral Anticoagulants
Dabigatran
Dosing | Discontinuation for Surgery and Interventions | Warnings and Precautions | Adverse Reactions | Use in Specific Populations Such as Pregnancy | Overdosage | Clinical Pharmacology | FDA Review of the RE-LY Data | A comparison of the RE-LY and Rocket AF Trials | Estimates of Cost Per Year of Life Saved for Dabigatran
Rate and Rhythm Control
Rate Control
Cardioversion
Overview | Electrical Cardioversion | Pharmacological Cardioversion
Ablation
Catheter Ablation | AV Nodal Ablation | Surgical Ablation